The Supreme Court handed down a pair of decisions that represent a significant victory for the pharmaceutical industry. A 5-4 ruling shields generic drugmakers from failure-to-warn lawsuits as long as their product labels are identical to those of brand-name drugmakers. A 6-3 decision strikes down a law in Vermont restricting the collection and sale of prescription-drug data.

Related Summaries